Paper Details

  1. Home
  2. Paper Details

A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.

Author: Al-MakkiAkram, BousherAva, SheplerBrian, SuttonJames

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Sucroferric oxyhydroxide, a new phosphate binder, shows promise in managing hyperphosphatemia in patients with chronic kidney disease, but more research is needed to determine its optimal role.
Paper Details　
Original Abstract of the Article :
Sucroferric oxyhydroxide is the newest phosphate binder to receive US Food and Drug Administration approval for patients on dialysis. The purpose of this review is to critically evaluate the studies that have been conducted with this medication and determine where it may fit in the clinician's overa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2014.09.021

データ提供：米国国立医学図書館（NLM）

Sucroferric Oxyhydroxide: A New Phosphate Binder for Dialysis Patients

Hyperphosphatemia, an elevated level of phosphate in the blood, is a common problem for patients undergoing dialysis. Sucroferric oxyhydroxide is a recently approved phosphate binder that aims to address this issue. This review critically evaluates the available studies on this medication and explores its potential role in the treatment of hyperphosphatemia in dialysis patients.

A New Option for Phosphate Binding: Evaluating Sucroferric Oxyhydroxide

This review provides a comprehensive overview of the current knowledge on sucroferric oxyhydroxide as a phosphate binder for dialysis patients. The evaluation of existing research is crucial for informing clinical decision-making and optimizing patient care.

Managing Hyperphosphatemia: A Multifaceted Approach for Dialysis Patients

Maintaining phosphate levels within a healthy range is essential for dialysis patients. This review emphasizes the importance of a multifaceted approach to managing hyperphosphatemia, including dietary modifications, lifestyle changes, and appropriate medication. The introduction of new phosphate binders like sucroferric oxyhydroxide offers additional options for clinicians to tailor treatment strategies to individual patients' needs.

Dr. Camel's Conclusion

The desert of chronic kidney disease can be harsh and unforgiving, and managing hyperphosphatemia is a key challenge for dialysis patients. This review provides a valuable overview of sucroferric oxyhydroxide, a new phosphate binder that offers a glimmer of hope for improving the management of this condition. Just as a camel relies on its ability to adapt to the desert environment, patients on dialysis need access to effective treatments and personalized care to thrive. This review is a valuable resource for clinicians seeking to provide optimal care for their patients.
Date :
  1. Date Completed 2016-03-23
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25450474

DOI: Digital Object Identifier

10.1016/j.clinthera.2014.09.021

Related Literature

Article Analysis
・Side Effects of sevelamer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.